YP
DMAC icon

YANKCOM Partnership’s DiaMedica Therapeutics DMAC Stock Holding History

YANKCOM Partnership’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$1.35K – 331
2026
Q1 		$1.35K Hold
200
– – ﹤0.01% 343
2025
Q4 		$1.59K Buy
+200
New +$1.5K ﹤0.01% 354

Other funds holding DMAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MW
Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
MWM
Meridian Wealth Management Lexington, Kentucky $3.25B AUM 41% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
CFP
Catalyst Financial Partners Boston, Massachusetts $1.01B AUM 36.54% 1-Year Est. Return

YANKCOM Partnership's DMAC Position: Q2 2026 in Review

YANKCOM Partnership sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 200 shares — an estimated $1.35K sold.

YANKCOM Partnership first reported a position in DMAC in Q4 2025 and held it in 2 quarters. The position peaked at $1.59K in Q4 2025. 30 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • YANKCOM Partnership reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • YANKCOM Partnership sold 200 DiaMedica Therapeutics shares in Q2 2026, an estimated $1.35K.
  • YANKCOM Partnership first reported a position in DiaMedica Therapeutics in Q4 2025 and held it in 2 quarters.
  • YANKCOM Partnership's DiaMedica Therapeutics position peaked at $1.59K in Q4 2025.
  • 30 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on YANKCOM Partnership's 13F filing for Q2 2026, filed 21 Jul 2026.